Morning Breakouts

Latest KFF Health News Stories

Generic Drugs, Antibiotics Get A Boost

Morning Briefing

Ro plans to supply generics of Lipitor and Norvasc through its virtual mail-order company. Also in the news: Lawmakers want to create a new payment model to encourage drugmakers to create antibiotics; and biotech firm G1 Therapeutics announces a CEO change.

Feds Charge 345 People With Health Care Fraud

Morning Briefing

The medical professionals are accused of submitting a total of $6 billion in bad claims for telehealth and substance abuse treatment, among other services. Also in the news: Clear View Behavioral Health in Colorado will lose its license; Anthem settles a cyberattack case; and hospitals are warned about Ryuk ransomware.

AstraZeneca, Moderna Hit Speed Bumps In Vaccine Race; Pfizer Watched Closely

Morning Briefing

News outlets report the latest on rapid coronavirus vaccine development efforts by pharmaceutical companies that could secure U.S. emergency use approval, and the push from President Donald Trump to reach that goal before Election Day.

Veterans Affairs Set To Unveil New Electronic Health Record System

Morning Briefing

The rollout was originally intended for July but was postponed because of the pandemic. The first site — Mann-Grandstaff VA Medical Center in Spokane, Washington — will go live on the new Cerner Corp. system on Oct. 24.

Trump Fueled 38% Of Pandemic Misinformation, Conspiracies: Study

Morning Briefing

“We conclude that the President of the United States was likely the largest driver of the COVID-19 misinformation ‘infodemic,'” said Cornell University researchers after analyzing 38 million English-language online articles about the pandemic. Other reports of President Donald Trump twisting the facts are also in the news.

Drugmakers Jacked Up Prices To Inflate Profits, House Probe Finds

Morning Briefing

Democrats on the House Oversight Committee began releasing two investigation reports that cite internal company documents on the day the CEOs of Teva, Celgene and Bristol Myers Squibb testified before the panel. Amgen, Mallinckrodt and Novartis executives are scheduled to appear Thursday.